肿瘤乏氧显像剂的研究进展  

Advances in study of tumor hypoxia imaging agents

作　　者：汪会[1] 徐慧琴[1] 

机构地区：[1]安徽医科大学第一附属医院核医学科,合肥230022

出　　处：《国际放射医学核医学杂志》2012年第6期366-370,共5页International Journal of Radiation Medicine and Nuclear Medicine

基　　金：安徽省科技计划项目

摘　　要：实体瘤快速生长，中央区血供不充分，导致乏氧区存在。而乏氧肿瘤细胞是影响肿瘤治疗效果的主要因素。乏氧显像剂能选择性地滞留在乏氧组织或细胞中，通过PET或SPECT可无创性评估实体瘤的乏氧状态，对肿瘤的治疗指导、疗效评价和预后判断具有很大的实用价值。该文简要介绍了乏氧显像剂的研究进展。Solid tumors cause regional hypoxia when they outgrow the blood supply. The presence of hypoxia cells within the tumor is the primary factor influencing the effect of therapy. Hypoxia imaging agents selectively accumulate in the oxygen deficient organizations or cells that can be detected by the non-invasive methods such as PET and SPECT. It has great practical value in guiding treatment, evaluating efficacy and accessing prognosis. This review briefly introduces the research progress of tumor hypoxia imaging agents.

关 键 词：肿瘤 正电子发射断层显像术 体层摄影术 发射型计算机 单光子 乏氧显像剂 

分 类 号：R730.44[医药卫生—肿瘤]